Bloomberg Law
Nov. 30, 2022, 2:34 PM

Eisai, Biogen Alzheimer’s Drug Trial Spurs Questions on Benefits

Robert Langreth
Robert Langreth
Bloomberg News

Eisai Co.’s much-anticipated findings on its experimental Alzheimer’s drug provided tinder for a debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Lecanemab, developed with help from Biogen Inc., cleared plaque that clogs patients’ brains and slowed their mental decline by 27% over 18 months. Yet the improvements came at the price of side effects like brain swelling and bleeding in more than one in five people on the medicine, compared to 10% of those who received a placebo.

Eisai offices in Nutley, New Jersey.
Source: PR Newswire

The findings presented at the Clinical Trials on Alzheimer’s Disease conference ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.